10-Q
Quarterly Report
Translational Development Acquisition Corp. TDAC TDACU TDACW
0001410578-25-001812
- Filed
- Aug 14, 2025 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Operating Cash Flow | Q2 2025 · Jun 30, 2025 | −$402.92K |
| Cash And Equivalents | Q2 2025 · Jun 30, 2025 | $35.26K |
| Cash And Equivalents | Q2 2025 · Dec 31, 2024 | $438.17K |
| Stockholders Equity | Q2 2025 · Jun 30, 2025 | −$6.17M |
| Stockholders Equity | Q2 2025 · Mar 31, 2025 | −$5.94M |
| Stockholders Equity | Q2 2025 · Dec 31, 2024 | −$5.6M |
| Stockholders Equity | Q2 2025 · Jun 30, 2024 | −$509.34K |
| Stockholders Equity | Q2 2025 · Mar 31, 2024 | −$507.66K |
| Stockholders Equity | Q2 2025 · Dec 31, 2023 | −$507.66K |
| Current Liabilities | Q2 2025 · Jun 30, 2025 | $284.68K |
| Current Liabilities | Q2 2025 · Dec 31, 2024 | $210.3K |
| Total Liabilities | Q2 2025 · Jun 30, 2025 | $6.32M |
| Total Liabilities | Q2 2025 · Dec 31, 2024 | $6.25M |
| Current Assets | Q2 2025 · Jun 30, 2025 | $156.08K |
| Current Assets | Q2 2025 · Dec 31, 2024 | $650.23K |
| Total Assets | Q2 2025 · Jun 30, 2025 | $178.18M |
| Total Assets | Q2 2025 · Dec 31, 2024 | $175M |
| Sga Expense | Q2 2025 · Jun 30, 2025 | $221.13K |
| Sga Expense | Q2 2025 · Jun 30, 2025 | $568.54K |
| Sga Expense | Q2 2025 · Jun 30, 2024 | $1.69K |
| Sga Expense | Q2 2025 · Jun 30, 2024 | $1.69K |
| Net Income | Q2 2025 · Jun 30, 2025 | $1.62M |
| Net Income | Q2 2025 · Jun 30, 2025 | $3.11M |
| Net Income | Q2 2025 · Mar 31, 2025 | $1.48M |
| Net Income | Q2 2025 · Jun 30, 2024 | −$1.69K |
| Net Income | Q2 2025 · Jun 30, 2024 | −$1.69K |
| Net Income | Q2 2025 · Mar 31, 2024 | $0 |
| Operating Income | Q2 2025 · Jun 30, 2025 | −$221.13K |
| Operating Income | Q2 2025 · Jun 30, 2025 | −$568.54K |
| Operating Income | Q2 2025 · Jun 30, 2024 | −$1.69K |
| Operating Income | Q2 2025 · Jun 30, 2024 | −$1.69K |